These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37701913)

  • 21. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
    Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
    Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
    Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
    Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
    [No Abstract]   [Full Text] [Related]  

  • 24. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
    Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
    BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
    Singh I; Patel R; Patel A; Jose V
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
    Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
    BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
    Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
    Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
    Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
    Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.
    Xie L; Zhu Y; Liang Z; Zhao Y; Zhou S; Chen J; Zhang H; Ding S; Wang L; Shao F
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):309-317. PubMed ID: 35112328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers.
    Raykova E; Farmahini Farahani M; Ivanova S; Azhdarzadeh M
    Expert Opin Biol Ther; 2022 Feb; 22(2):235-243. PubMed ID: 34405742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers.
    Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized, Double-Blind, Parallel Controlled, Single-Dose Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of the Infliximab Biosimilar CMAB008 and the Reference Product in Healthy Chinese Male Subjects.
    Zhou R; Chen Q; Hou S; Guo H; Li J; Qian W; Wang H; Ou L; Chen X; Jiang F; Jia J
    Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1028-1035. PubMed ID: 35778977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pharmacokinetic study comparing the biosimilar HEC14028 and Dulaglutide (Trulicity®) in healthy Chinese subjects.
    Gao X; Di Y; Lv Y; Luan Y; Xiong Y; Xu Y; Li Y; Guo L; Li X; Deng L; Zhuang Y; Hou J
    Clin Transl Sci; 2024 Apr; 17(4):e13775. PubMed ID: 38651744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera
    Han X; Zhang M; Wang H; Zhang Q; Li W; Hao M; Gao Y; Jin J; Ren H; Tang Y; Hong X; Ke X; Su H; Gui L; Luo J; Xie L; Gai W; Shi Y
    Chin J Cancer Res; 2022 Dec; 34(6):601-611. PubMed ID: 36714342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
.
    Zhang H; Zhu X; Wei H; Li C; Chen H; Li X; Wu M; Liu J; Chen G; Zhou H; Zheng S; Ding Y
    Int J Clin Pharmacol Ther; 2019 Mar; 57(3):167-174. PubMed ID: 30663977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra
    Zhang H; Li X; Liu J; Li C; Wu M; Zhu X; Sun J; Fang M; Ding Y
    Ann Med; 2021 Dec; 53(1):375-383. PubMed ID: 33629921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.
    Lee HA; Jang H; Jeong D; Kim Y; Fuhr R
    Int J Clin Pharmacol Ther; 2022 Jun; 60(6):269-279. PubMed ID: 35348111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.